

CURRICULUM VITAE

DR. MANGESH THORAT

MBBS, MS, DNB, FEBS, CEBS, PhD

CONTACT DETAILS

Mangesh Atmaram Thorat
Email: thoratmangesh@gmail.com

ACADEMIC QUALIFICATIONS

MBBS (1999). Pune University, India (Medical Licensing Examination)
MS (General Surgery) (2002). Mumbai University (Tata Memorial Hospital)
DNB (General Surgery) (2002). National Board of Examinations, New Delhi
FEBS (Breast Surgery) (2019). UEMS European Board of Surgery
PhD (Cancer Prevention) (2016). University of London, UK

Specialist Certification:

BRESO - European Certification in Breast Surgical Oncology (2024)

Memberships:

MNAMS (National Academy of Medical Sciences, India, Life Member)

British Breast Group

BASO ~ The Association for Cancer Surgery

Medical council registrations:

General Medical Council, UK – Ref no. **7031116**
(Registered with license to practice since 01 January 2011)

Maharashtra Medical Council, Maharashtra, India – Reg no. **88985** (Registered with license to practice since 02 February 1999)

A few words about myself.....

I trained in India as a surgical oncologist with special interest in breast cancer. Training at Tata Memorial Hospital also included significant exposure to clinical research and audit. I subsequently moved to USA and then UK to conduct research on breast cancer biomarkers. Main areas of my current research include diagnostic and prognostic biomarkers in breast

cancer, prevention of cancers – particularly breast cancer and role of aspirin in prevention. I previously served as Deputy Director (Clinical) for Cancer Prevention Trials Unit at King's Health Partners and I remain involved in the development of studies/trials, particularly for cancer prevention. I am also involved in other scientific and academic activities like editorial roles, peer review for several journals, mentoring medical students and junior clinicians; assessment of medical students and medical school applicants.



AWARDS AND ACHIEVEMENTS

- ❖ Among **top 0.5 %** (4th out of about 800) students in the **Final M.B.B.S.** examination (**Medical Licensing Examination**) of University of Pune, November 1997.
- ❖ **Third rank** in the subject of Biochemistry at first M.B.B.S. examination, University of Pune, October 1994.
- ❖ **Third rank** in the subject of Oto-rhino-laryngology at third M.B.B.S. examination, University of Pune, November 1997.
- ❖ **First rank in whole state** in subject of **Physics** at Maharashtra state **H.S.C. Board** examination, March 1993.
- ❖ Recipient of **ASCO Merit Award** (*Twice: Year 2007; Year 2008*).
- ❖ Recipient of **SABCS Clinical Scholar Award** (*Year 2015*).
- ❖ Recipient of **EORTC Travel Grant** (Diagnostic Development Tutorial, Brussels 2013).
- ❖ Recipient of **AACR Travel Grant** (Molecular Biology Workshop, Aspen 2007).
- ❖ Recipient of **IARC Travel Grant** (Epidemiology Summer School, Lyon 2006).

- ❖ Recipient of **Lynn Sage Travel Grant** (Breast Cancer Symposium; **Twice**: Year **2007**; Year **2008**).
- ❖ Recipient of **Wellcome Trust Value in People Award** (Year **2008/09**).

- ❖ International Journal of Surgery "[Reviewer of the Month](#)" March 2012.

JOURNAL AND OTHER APPOINTMENTS

❖ Editorial appointments

Editorial Consultant (in past): The **Lancet**.

Senior Editor: **Int J Surgery**

Associate Editor: **npj Breast Cancer**

Subject Editor: **BJC Reports**

Associate Editor: **Frontiers in Oncology**

Editorial Board: **Biomedicines**

Editorial Board: **South Asian J Cancer**

❖ Academic roles

PhD examiner – University of Leicester

Executive Board member: International Cancer Prevention Society (**ICAPS**)

❖ Scientific organisations

Steering Committee: UK Therapeutic Cancer Prevention Network (**UK-TCPN**)

Steering Committee: Cancer Prevention Europe (**CPE**)

European Code Against Cancer 5 (**ECAC5**) working group

Steering Committee (in past): Early Cancer Detection Europe (**ECaDE**)

❖ Assessment/Funding panels

Cancer Research UK (**CRUK**) Prevention and Population Research Committee (**PPRC**) Expert Review Panel (*ad hoc member*)

Advisory Committee on Clinical Impact Awards (**ACCIA**) - sub-committee member

The Norwegian Cancer Society (**NCS**) - Research Peer-Review Committee member

Member (in past): CRUK Clinical Trials Awards and Advisory Committee (**CTAAC**).

❖ Reviewer (past and present) ([WoS Profile](#): <http://bit.ly/MTrev>)

Lancet

Lancet Oncology

BMJ

Annals of Internal Medicine

PLOS Medicine

JAMA Oncology

BMC Medicine

Annals of Oncology

EBioMedicine

International Journal of Cancer

European Journal of Cancer

British Journal of Cancer

Cancer Epidemiology

J Am Coll Cardiol

CEBP

BMC Cancer

JNCI Cancer Spectrum

European Journal of Cancer Prevention

International Journal of Surgery

Breast Cancer Research

The Breast (Elsevier)

Clinical Breast Cancer

Cancer Treatment Reviews

American Journal of Cardiovascular Drugs

PLOS One

Cancer Cell International

Frontiers Pharmacology

Cancer Biomarkers

South Asian J Cancer

Future Oncology

Personalized Medicine (Future Medicine)

Journal of Clinical Oncology

Journal of Pathology

Journal of Surgical Oncology

Journal of Clinical Pathology

National Medical Journal of India

Acta Obstetricia et Gynecologica Scandinavica (AOGS)

- Assessment/Funding panels

NIHR-HTA

Health Research Board – Ireland

The Netherlands Organisation for Health Research and Development (ZonMW)

Italian Medicines Agency (AIFA)

The Icelandic Research Fund (IRF)

Fonds de la Recherche Scientifique - FNRS, Belgium

CURRICULUM VITAE

CURRENT APPOINTMENTS

Clinical Lead & Locum Consultant (02.01.2024 to date): Breast Surgery, Homerton University Hospital, London

Honorary Reader (Queen Mary University of London) (01.10.2023 to date): Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health

WORK EXPERIENCE & TRAINING

Clinical Training and Experience:

Internship (21.01.1998 to 20.01.1999): B.J. Medical College & Sassoon General Hospitals, Pune, India.

Post graduate training (SHO) (26.03.1999 to 27.04.2002): Tata Memorial Hospital and K.E.M Hospital, Mumbai, India

Research Fellow (01.08.2002 to 31.01.2003): Breast Services, Tata Memorial Hospital

Clinical Fellow (01.02.2003 to 31.08.2003): Breast Services, Tata Memorial Hospital

Senior Registrar II & III (01.09.2003 to 31.08.2005): General Surgical Oncology, Tata Memorial Hospital

Specialist Senior Registrar (01.09.2005 to 31.10.2006): Breast Services, Tata Memorial Hospital

Bank locum consultant and Honorary Clinical Lecturer (01.04.2014 to 30.04.2018): Breast Surgery, Division of Surgery and Interventional Science, Whittington Hospital, London.

Honorary Clinical Fellow (11.06.2018 to 21.04.2019): Breast Surgery, Guy's Hospital, London.

Senior Clinical Fellow (22.04.2019 to 04.12.2021): Breast Surgery, Guy's Hospital, Great Maze Pond, London

Acting Locum Consultant (05.12.2021 to 30.06.2022): Breast Surgery, Guy's Hospital, Great Maze Pond, London

Locum Consultant (01.07.2022 to 01.01.2024): Breast Surgery, Guy's Hospital, Great Maze Pond, London

Honorary Consultant (02.01.2024 to 31.12.2024): Breast Surgery, Guy's Hospital, Great Maze Pond, London

Bank locum consultant (01.12.2020 to 31.12.2024): Breast Surgery, University Hospital Lewisham, London

Research Training and Experience:

Post-Doctoral Research Fellow (20.11.2006 to 08.02.2009): IU Simon Cancer Centre Translational Genomics Core and Department of Pathology and Laboratory Medicine, IU School of Medicine, IUPUI, Indianapolis, Indiana, USA

Research Fellow (09.02.2009 to 31.03.2020): Centre for Cancer Prevention, (CCP), Wolfson Institute of Preventive Medicine. Barts & The London School of Medicine and Dentistry, Queen Mary University of London

Honorary Senior Lecturer (01.04.2020 to 30.09.2023): Centre for Cancer Prevention, Wolfson Institute of Population Health; Barts & The London Faculty of Medicine and Dentistry, Queen Mary University of London

Deputy Director (Clinical) - Cancer Prevention Trials Unit (King's Health Partners) (01.07.2016 to 31.03.2023) School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London.

Visiting Senior Lecturer (King's College London) (01.01.2019 to 31.03.2025): School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London

Additional Training:

❖ Attended **Epidemiology Summer School** at International Agency for Research on Cancer (IARC) at Lyon, France from 26th June to 14th July, covering **Descriptive, Analytical and Molecular Epidemiology**.

- ❖ Attended **Molecular Biology in Clinical Oncology** workshop conducted by **AACR**, in Aspen, USA from 29th June to 7th July 2007.
- ❖ **Good Clinical Practice (GCP)** in Clinical Trials of Investigational Medical Products (CTIMPs) training: Queen Mary, University of London 20th March 2009. **Refresher** course – 31st January 2011, 20th February 2013, 10th April 2015, 25th April 2017, 20th March 2019, 29th January 2022, 31st July 2024.
- ❖ **Leadership and Managing Teams** – Institute of Leadership and Management certified course: Queen Mary, University of London 8th and 15th October 2012.
- ❖ **Advanced Life Support (ALS) provider** – 23rd and 24th April 2016 at the North Middlesex Hospital.
- ❖ **ESSO Advanced Course on Oncoplastic Breast Surgery**, Madrid, Spain, 13-15 June 2019
- ❖ **International Breast Surgical Ultrasound (SENUS) Course**: 21-22 October 2023, Istanbul, Turkiye

RESEARCH EXPERIENCE

Epidemiological research:

I conceived, designed & conducted an epidemiological study looking at prevalence and principle determinants of protein energy malnutrition (PEM) among rural primary school children in India. In this study conducted during my internship (1998), we collected epidemiological data from **3500** school children and found prevalence of protein energy malnutrition at a staggering 67%. The hypothesis that addiction in parents is one of the prime determinants of PEM was also validated in this study.

I have been a member of international panels of experts convened to discuss i.) the role of aspirin in cancer prevention ii.) Prostate cancer prevention and iii.) Colorectal cancer prevention. Recently, I collated and modelled UK population-based data to estimate benefits and harms of prophylactic aspirin (see PUBLICATIONS below).

Clinical Research:

During past few years, I have been involved in design and conduct of various new clinical trials mainly dealing with various aspects of breast cancer research. Please see below for ongoing and recently completed clinical trials.

Laboratory Research:

At Tata Memorial Hospital, I was directly involved in design and planning of laboratory research component of above-mentioned trials and few other laboratory based projects like assessment of cancer cell dissemination.

At IU School of Medicine, I conducted studies involving high-throughput gene expression analysis in breast cancer and other cancers. Apart from this I worked on qRT-PCR for sentinel nodes, a few IHC based projects dealing with new prognostic/predictive/therapeutic marker identification and in vitro (cell line) studies for drug evaluation and gene-expression based surrogate marker development for use in a clinical trial.

My current work is focused around identification of prognostic and predictive biomarkers in DCIS as well as markers and molecular changes during DCIS progression to invasive breast cancer; using material from UK/ANZ DCIS trial in a case:control and cohort design. The project employs various molecular techniques like qRT-PCR, IHC and PCR-Pyrosequencing to investigate mRNA, protein and DNA methylation biomarkers. I was also associated with molecular studies to identify diagnostic and prognostic biomarkers in Prostate cancer using resources from Trans-Atlantic Prostate Group cohort.

CLINICAL TRIALS

Completed trials:

Feasibility of IBIS-III: An International Breast Intervention Study investigating metformin,

anastrozole and zoledronic acid in breast cancer survivors following 5 years of adjuvant treatment. (Role: **Chief Investigator**)

PREDICTORS 5.0: A study comparing the stability for human papillomavirus testing of three dry vaginal self-samples taken by women attending a colposcopy clinic. (Role: **Chief Investigator**)

VIVIANE: Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older. (Role: **Principal Investigator**)

HPV-052 EXT 008: Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects. (Role: **Principal Investigator**)

Cepheid Protocol 082B: Technical Evaluation of the Xpert® HPV Assay in a General Screening Population. (Role: **Principal Investigator**)

Cepheid Protocol 083B: Precision and Reproducibility Evaluation of the Xpert® HPV Assay. (Role: **Principal Investigator**)

TSC/DMC member:

ADD-Aspirin

CaPP3

GISTAR

COLO-PREVENT

TARGIT-B

TOGAS

EUCanScreen

TEACHING EXPERIENCE

- Faculty for the European School of Oncology and Ulm University: **Certificate of Competence in Breast Cancer Programme** (online lecture module).
- Faculty for e-learning modules for **European Code Against Cancer** hosted by IARC.
- Mentor in the **College of European School of Oncology** (ESCO) mentorship programme
- Classroom & Clinic room Clinical skills teaching

Previously,

- Faculty for the “**Clinical Research Design**” course by King’s Health Partners (KHP), in collaboration with the University of California San Francisco (UCSF).
- Personal mentor for QMUL School of Medicine & Dentistry students.
- **Cancer Prevention and Screening** module of MSc Oncology course at Queen Mary University.

PUBLICATIONS

Research

1. Sinha AP, Jurrius P, van Schelt AS, et al. Tumor Biomechanics Quantified Using MR Elastography to Predict Response to Neoadjuvant Chemotherapy in Individuals with Breast Cancer. *Radiol Imaging Cancer*. 2025 Mar;7(2):e240138. doi: 10.1148/rycan.240138.
2. Li H, Aggarwal A, Toro P, Fu P, Badve SS, Cuzick J, Madabhushi A, Thorat MA. A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial. *Lancet Digit Health*. 2024. doi: 10.1016/S2589-7500(24)00116-X.

LINKS

[PubMed](#)

ORCID iD: [0000-0001-8673-5320](#)

Researcher ID: [A-9787-2008](#)

Scopus Author ID [10439116700](#)

[MEDIA COVERAGE](#)

3. McDermott KT, Noake C, Wolff R, Bauld L Espina C, Foucaud J, Steindorf K, **Thorat MA**, Weijenberg M, and Schüz J, Kleijnen J. Digital interventions to moderate physical inactivity and/or nutrition in young people: a Cancer Prevention Europe overview of systematic reviews. *Front. Digit. Health* (2023) 5: 1185586. doi: 10.3389/fdgth.2023.1185586
4. McDermott KT, Noake C, Wolff R, Espina C, Foucaud J, Steindorf K, Schüz J, **Thorat MA**, Weijenberg M, Bauld L and Kleijnen J. Digital interventions to moderate alcohol consumption in young people: a Cancer Prevention Europe overview of systematic reviews. *Front. Digit. Health* (2023) 5:1178407. doi: 10.3389/fdgth.2023.1178407.
5. Atakpa EC, **Thorat MA**, Cuzick J, Brentnall AR. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. *Cochrane Database Syst Rev*. 2021 Oct 26;10(10):CD013091. doi: [10.1002/14651858.CD013091.pub2](https://doi.org/10.1002/14651858.CD013091.pub2).
6. Hall LH, Thorneloe R, Rodriguez-Lopez R, Grice A, **Thorat MA**, Bradbury K, Kamble MW, Okoli GN, Powell D, Beeken RJ. Delivering brief physical activity interventions in primary care: a systematic review. *Br J Gen Pract*. 2021 Sep 20: BJGP.2021.0312. doi: 10.3399/BJGP.2021.0312.
7. **Thorat MA**, Levey PM, Jones JL, et al. Prognostic and predictive value of HER2 expression in ductal carcinoma *in situ*: Results from the UK/ANZ DCIS Trial. *Clin Cancer Res*. 2021 October 1;27(19): 5317-5324; doi:[10.1158/1078-0432.CCR-21-1239](https://doi.org/10.1158/1078-0432.CCR-21-1239).
8. Lloyd KE, Hall LH, Ziegler L, Smith SG; **ENGAGE investigators**. Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study. *Breast Cancer Res Treat*. 2021 Aug;188(3):703-712. doi: 10.1007/s10549-021-06183-x.
9. **Thorat MA**, Levey PM, Jones JL, et al. Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma *in situ*: Results from the UK/ANZ DCIS Trial. *Clin Cancer Res*. 2021 May 15;27(10):2861-2867. doi: [10.1158/1078-0432.CCR-20-4635](https://doi.org/10.1158/1078-0432.CCR-20-4635).
10. Li H, Whitney J, Bera K, Gilmore H, **Thorat MA**, Badve S, Madabhushi A. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma *in situ*: preliminary findings. *Breast Cancer Res*. 2019;21(1):114. doi: 10.1186/s13058-019-1200-6.
11. Thorneloe RJ, Horne R, Side L, et al. Beliefs about Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results from a Multicenter Prospective Study. *Clin Breast Cancer*. 2018. doi: 10.1016/j.clbc.2018.10.008
12. Cuzick J, Sestak I, **Thorat MA**. Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. *Breast*. 2015. doi: 10.1016/j.breast.2015.07.013.
13. **Thorat MA**, Cuzick J. Prophylactic use of aspirin: Systematic review of harms and approaches to mitigation in the general population. *Eur J Epidemiol*. 2015; 30(1):5-18.
14. Cuzick J, **Thorat MA**, Bosetti C, Brown PH, Burn J, Cook NR et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. *Ann Oncol* 2015; 26(1):47-57. **Media Coverage:** <http://bit.ly/MATmedia>
15. Cuzick J, Cuschieri K, Denton K, Hopkins M, **Thorat MA**, Wright C, et al. Performance of the Xpert HPV assay in women attending for cervical screening. *Papillomavirus Research*. 2015;1:32-7.
16. Vasiljević N, Ahmad AS, **Thorat MA**, Fisher G, Berney DM, Møller H et al. DNA methylation gene-based models indicating independent poor outcome in prostate cancer. *BMC Cancer* DOI: 10.1186/1471-2407-14-655.
17. Gökmen-Polar Y, **Thorat MA**, Sojitra P, Saxena R, Badve S. FOXP3 expression and nodal metastasis of breast cancer. *Cell Oncol* (Dordr). 2013;36(5):405-9.
18. Kim DC*, **Thorat MA***, Lee MR, Cho SH, Vasiljevic N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, Lorincz AT. Quantitative DNA methylation and recurrence of breast cancer: A study of 30 candidate genes. *DCK and MAT contributed equally*. *Cancer Biomarkers* 2012;11(2-3):75-88.
19. Vasiljević N, Ahmad AS, Beesley C, **Thorat MA**, Fisher G, Berney DM et al. Association between DNA methylation of HSPB and death in low Gleason score prostate cancer. *Prostate Cancer and Prostatic Disease* 2013;16(1):35-40.
20. Ademuyiwa FO, Miller A, O'Connor T, Edge SB, **Thorat MA**, Sledge GW, Levine E, Badve S. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. *Breast Cancer Res Treat* 2011 ;126(3):797-802.
21. Vasiljević N, Wu K, Brentnall AR, Kim DC, **Thorat MA**, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT. Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer using

Pyrosequencing. **Disease Markers** 2011;30(4):151-61.

22. **Thorat MA**, Thorat PM, Vaidya HJ, Vaidya JS. Analysis of temporal trends in the BMJ archive. **BMJ** 2010;340:c3306.

23. McCune K, Mehta R, **Thorat MA**, Badve S, Nakshatri H. Loss of ER α and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. **Oncol Rep**. 2010 Nov;24(5):1233-9.

24. Appaiah H, Bhat-Nakshatri P, Mehta R, **Thorat M**, Badve S, Nakshatri H. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. **Cancer Biol Ther** 2010; 10(6): 600-614.

25. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, **Thorat M**, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H. Subcellular Localization of Activated AKT in ER and PR Expressing Breast Cancers: Potential Clinical Implications. **Am J Path** 2010; 176(5):2139-49.

26. McCune K, Bhat-Nakshatri P, **Thorat MA**, Nephew K, Badve S, Nakshatri H. Disruption of Estrogen Receptor, GATA-3, and FOXA1 Transcription Factor Network by Insulin-Inducible T-bet: Implications in Hormone-Dependent Breast Cancer. **Cancer Research** 2010; 70(2):685-96.

27. Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, **Thorat MA**, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW, Badve S. Differential sub-cellular expression of protein kinase C betall in breast cancer – correlation with breast cancer subtypes. **Breast Cancer Research and Treatment** 2010. 124(2):327-335.

28. Ademuyiwa FO, **Thorat MA**, Jain R, Nakshatri H, Badve S. Expression of Forkhead box protein A1, a marker of Luminal A Type Breast Cancer, Parallels Low Oncotype DX 21-Gene Recurrence Scores. **Modern Pathology** 2010; 23: 270-75.

29. Resetkova E, Reis-Filho JS, Jain RK, Mehta R, **Thorat MA**, Nakshatri H, Badve S. Prognostic impact of ALDH1 In Breast Cancer - A story of stem cells and tumor microenvironment. **Breast Cancer Research and Treatment** 2009; 117(2):297-303.

30. **Thorat MA**, Mehrotra S, Morimiya A, Badve S. COX-2 Expression does not correlate with microvessel density in Breast Cancer. **Pathobiology** 2009; 76:39-44.

31. **Thorat MA**, Rangole A, Nadkarni MS, Parmar V, Badwe RA. Revision Surgery for Breast Cancer: Single Institution Experience. **Cancer** 2008; 113(8 suppl):2347-52.

32. **Thorat MA**, Turbin D, Morimiya A, Leung S, Zhang Q, Jeng MH, Huntsman DG, Nakshatri H, Badve S. Amplified in Breast cancer 1 (AIB1) expression in breast cancer. **Histopathology** 2008; 53: 634-41.

33. Hammoud ZT, Badve S, Zhao Q, Li L, Saxena R, **Thorat MA**, Morimiya A, Rieger KM, Kesler KA. Differential gene expression profiling of esophageal adenocarcinoma. **J Thorac Cardiovasc Surg** 2009 ;137(4):829-34.

34. **Thorat MA**, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S. FOXA1 expression in breast cancer is associated with Luminal subtype and good prognosis. **Journal of Clinical Pathology** 2008; 61:327-332.

35. **Thorat MA**, Morimiya A, Mehrotra S, Konger R, Badve SS. Prostanoid receptor EP1 Expression in Breast Cancer. **Modern Pathology** 2008; 21:15-21.

36. Badve S, Turbin D, **Thorat MA**, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. FOXA1 Expression in Breast Cancer - Correlation with Luminal Subtype A and Survival. **Clinical Cancer Research**. 2007; 13(15): 4415-4421.

Editorials, Opinion pieces, Critical Analysis, Hypotheses

37. **Thorat MA**. An aspirin a day keeps cancer at bay. **BJC Rep**. 2025 Apr 11;3(1):23. doi: 10.1038/s44276-025-00138-1.

38. **Thorat MA**. COMETgazing - interesting insights, lessons for clinical practice and a call for more precision using the biomarkerSCOPE. **Oncotarget**. 2025 Mar 10;16:138-139. doi: 10.18632/oncotarget.28698.

39. **Thorat MA**. Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy. **JAMA Oncol**. 2024. doi: 10.1001/jamaoncol.2024.4569.

40. **Thorat MA**, Cuzick J, Chan AT. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. **JAMA**. 2024;332(13):1111-1112. doi: 10.1001/jama.2024.15497.

41. Garg N, **Thorat MA**. A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition

of the research question and a robust study design. *Cancer*. 2024. doi: 10.1002/cncr.35495.

42. Garg N, Thorat MA, Kothari AS. The SOUND Randomized Clinical Trial Results. *JAMA Oncol*. 2024. doi: 10.1001/jamaoncol.2024.0128.
43. Garg N, Thorat MA. Letter to the Editor - Cost-Efficacy Analysis of Use of Frozen Section Histology for Margin Assessment During Breast Conservation Surgery in Breast Cancer Patients. *World Journal of Surgery* 2023; 47(12): 3451-3452. doi: 10.1007/s00268-023-07186-z.
44. Thorat MA. Multiclonality of ER expression in DCIS – Implications for clinical practice and future research. *Oncotarget*. 2023; 14: 719-720. doi: 10.18632/oncotarget.28450
45. Garg N, Thorat MA. HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment! *Oncoscience*. 2023;10:1-3. doi: 10.18632/oncoscience.572.
46. Ryan J O Dowling; Kevin Kalinsky; Daniel F Hayes et al Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. *JNCI CANCER SPECTRUM* 2019; DOI: 10.1093/JNCICS/PKZ050
47. Ryan J O Dowling; Joseph A Sparano; Pamela J Goodwin; et al. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. *JNCI CANCER SPECTRUM* 2019; DOI: 10.1093/JNCICS/PKZ049
48. Espina C, Bauld L, Bonanni B, et al. The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. *Tumori*. 2019. doi: 10.1177/0300891619851865.
49. Thorat MA. Liquid Biopsy for Cancer Diagnosis and Screening – The Promise and Challenges. *Annals Clin Biochem* 2019. doi: 10.1177/0004563219837592 (Editorial)
50. Thorat MA. Individualised benefit-harm balance of aspirin as primary prevention measure - a good proof-of-concept, but could have been better.... *BMC Med*. 2016 Jul 6;14(1):101. doi: 10.1186/s12916-016-0648-9. (Editorial)
51. Thorat MA. A major flaw in “Awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey”. *Maturitas*. 2016; 88: 45. doi: 10.1016/j.maturitas.2016.03.013.
52. Thorat MA. Sentinel lymph node assessment in breast cancer patients receiving neo-adjuvant chemotherapy: to biopsy before or after? *Int J Cancer*. 2015; 138(2):267-70. doi: 10.1002/ijc.29692. (Editorial)
53. Thorat MA. Tackling breast cancer in India. *Lancet*. 2012;379(9834):2340-1.
54. Thorat MA. Comment on "Dynamic response to heat -- a novel physical characteristic of breast cancer". *Int J Surgery* 2009; 7(2):173
55. Thorat MA. Five Genetic Variants Associated with Prostate Cancer. *N Engl J Med* 2008. 358; 25: 2740.
56. Thorat MA, Thornton H. MRI breast screening. *Lancet* 2008; 371:1415.
57. Thorat MA. What caused decline in US breast cancer incidence? *Nature Clinical Practice Oncology* 2008; 5(6):314-5. (Viewpoint article selected in Faculty-1000 Biology; <http://www.f1000biology.com/article/id/111204> 4)
58. Thorat MA. Should we undertake MRI breast screening trial? *Lancet* 2007; 370(9603):1902.
59. Thorat MA. Gene-signature-based prognostic tools in breast cancer: not yet. *Lancet* 2007; 369: 1428.
60. Thorat MA, Parmar V, Nadkarni MS, Badwe RA. Radiation therapy for ductal carcinoma in situ: is it really worth it? *J Clin Oncol*. 2007; 25(4):461-2.
61. Thorat M. Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. *Nature Clinical Practice Oncology* 2006; 3(12): E1.
62. Thorat MA. Medical research in India. *Lancet* 2006; 368: 643-44.
63. Badwe RA, D'cruz AK, Mistry RC, Tongaonkar HB, Shastry S, Thorat MA. Developing countries: An evolving opportunity for oncological research. *World Journal of Surgery*. 2006; 30(7): 1173-6.
64. Thorat MA. Herceptin in early breast cancer: A call for judicious use. *National Medical Journal of India* 2005; 18(6): 315-17.
65. Thorat MA. Are there distinct lymphatic flow patterns in the Breast? (Hypothesis) *Medical Hypothesis* 2006; 66(5): 1040-41.
66. Thorat M. Trastuzumab for early breast cancer. *Lancet* 2006; 367: 108.
67. Thorat MA, Badwe RA. Autoantibodies in Prostate cancer. *N Engl J Med* 2005. 353 (26): 2816
68. Thorat MA, Thorat PM. Privately managed versus Publicly managed primary healthcare. *National Medical Journal of India* 2005; 18 (5): 274-75.
69. Badwe RA, Thorat MA. Does primary tumor location have prognostic significance in operable

breast cancer? *Nature Clinical Practice Oncology* 2005, 2 (8): 396-97.

70. **Thorat M.** Optimum cancer care- an unaffordable goal? *Lancet Oncology* 2004; 5: 530.

71. Badwe RA, **Thorat MA**, Parmar VV. Sentinel-Node Biopsy in Breast Cancer. *N Engl J Med* 2003; 349(20): 1968.

72. Badwe RA, **Thorat MA**, Havaldar RW. Radical and Simple mastectomy. *N Engl J Med* 2002; 347(26): 2170.

Guidelines, Reviews and other articles

73. Tondare A, **Thorat MA**. De-escalation of axillary interventions in the management of breast cancer patients following neoadjuvant systemic treatment. *Transl Breast Cancer Res*. 2025 Apr 27;6:14. doi: 10.21037/tbcr-24-59.

74. Mathew G, Sohrabi C, et al; **PROCESS Group**. Preferred reporting of case series in surgery (PROCESS) 2023 guidelines. *Int J Surg*. 2023. doi: 10.1097/JS9.0000000000000940.

75. Sohrabi C, Mathew G et al. The SCARE 2023 guideline: Updating consensus surgical case report (SCARE) guidelines. *Int J Surg* 2023. doi: 10.1097/JS9.0000000000000373

76. Mathew G, Agha R; **STROCSS Group**. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. *Int J Surg*. 2021 Dec;96:106165. doi: 10.1016/j.ijsu.2021.106165.

77. Agha RA, Sohrabi C, Mathew G, et al & PROCESS Group. The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasEseries in Surgery (PROCESS) Guidelines. *Int J Surg*. 2020;84:231-235. doi: 10.1016/j.ijsu.2020.11.005

78. Agha RA, Franchi T, Sohrabi C, et al & SCARE Group. The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. *Int J Surg*. 2020;84:226-230. doi: 10.1016/j.ijsu.2020.10.034

79. Agha R, Abdall-Razak A, Crossley E, et al; STROCSS Group. STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. *Int J Surg*. 2019;72:156-165. doi: 10.1016/j.ijsu.2019.11.002.

80. **Thorat MA**, Balasubramanian R. Breast cancer prevention in high-risk women. *Best Pract Res Clin Obstet Gynaecol*. 2019. doi: 10.1016/j.bpobgyn.2019.11.006.

81. Agha RA, Borrelli MR, Farwana R, et al & PROCESS Group. The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. *Int J Surg*. 2018. 60, 279–282. doi:10.1016/j.ijsu.2018.10.031

82. Agha RA, Borrelli MR, Farwana R, et al. The SCARE 2018 Statement: Updating Consensus Surgical CAse REport (SCARE) Guidelines. *Int J Surg*. 2018. doi: 10.1016/j.ijsu.2018.10.028.

83. Agha RA, Borrelli MR, Vella-Baldacchino M, et al. The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. *Int J Surg*. 2017; 46:198-202. doi: 10.1016/j.ijsu.2017.08.586.

84. **Thorat MA**, Cuzick J. Preventing invasive breast cancer using endocrine therapy. *Breast*. 2017; 34 Suppl 1:S47-S54. doi: 10.1016/j.breast.2017.06.027.

85. Ussi AE, Reboli M, **Thorat MA**, Bietrix F, Fauvel AC, Hajduch M, et al. Assessing opportunities for coordinated R&D in early cancer detection and management in Europe. *Int J Cancer*. 2016. doi: 10.1002/ijc.30564.

86. Agha RA, Fowler AJ, Rajmohan S, et al. Preferred reporting of case series in surgery; the PROCESS guidelines. *Int J Surg*. 2016;36(Pt A):319-23.

87. Agha RA, Fowler AJ, Saeta A, et al. The SCARE Statement: Consensus-based surgical case report guidelines. *Int J Surg*. 2016;34:180-6.

88. DeCensi A, **Thorat MA**, Bonanni B, Smith SG, Cuzick J. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. *Ecancermedicalscience*. 2015; 9: 595. doi: 10.3332/ecancer.2015.595.

89. Pathmarajah P, Shah K, Taghipour K, Ramachandra S, **Thorat MA**, Chaudhry Z et al. Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: first report of a case in the UK. Accepted for publication in the *International Journal of Surgery Case Reports*.

90. Cuzick J, **Thorat MA**, Andriole G, Brawley OW, Brown PH, Culig Z et al. Prevention and early detection of prostate cancer. *Lancet Oncology*. 2014; 15(11): e484-e492.

91. Cuzick J, **Thorat MA**. PSA testing for prostate cancer screening--authors' reply. *Lancet Oncol*. 2015; 16(1):e3.

92. **Thorat MA**, Cuzick J. Reply to the letter to the editor 'the harms of low-dose aspirin prophylaxis are overstated' by P. Elwood and G. Morgan. *Ann Oncol*. 2015; 26(2):442-3.

93. **Thorat MA**, Cuzick J. Role of aspirin in cancer prevention. *Curr Oncol Rep* 2013;15(6):533-40.

94. Vaidya JS, Baldassarre G, **Thorat MA**, Massarut S. Role of Glucocorticoids in Breast Cancer. *Curr Pharm Des*. 2010;16(32):3593-600.

95. Basu S, Nair N, **Thorat M**, Shet TM. Uptake Characteristics of FDG in Multiple Juvenile Cellular

Fibroadenomata of the Breast: FDG-PET and Histopathologic Correlation. *Clin Nucl Med*. 2007; 32(3): 203-204.

96. **Thorat MA**, Datar RH, Joshi NN. Cancer immunotherapeutics: Raising the ante. *National Medical Journal of India* 2006; 19(3): 140-50.

BOOK

Cuzick J and **Thorat MA (Editors)**: Prostate Cancer Prevention (Series: Recent Results in Cancer Research) 2014. Publisher: Springer (ISBN-13: 978-3642451942)

BOOK CHAPTERS

Thorat MA, Badwe RA. Clinical trials and Evidence-Based Medicine. In "Current concepts in bone and soft tissue Tumors", textbook of Indian Orthopaedic Association. Arihant Publishers: Ch 25; 287-93.

Thorat MA, Aspirin, In *Encyclopedia of Cancer* (Third Edition), edited by Paolo Boffetta and Pierre Hainaut, Elsevier Inc, 2017. DOI: 10.1016/B978-0-12-801238-3.65131-0.

Tondare A, **Thorat MA**. Breast lumps in pregnancy. Differential Diagnosis in Obstetrics & Gynaecology (Third Edition). edited by Hollingworth T and Dalton JAW. CRC Press (Taylor & Francis Group, LLC), 2026.

Tondare A, **Thorat MA**. Breast tenderness in pregnancy and lactation. Differential Diagnosis in Obstetrics & Gynaecology (Third Edition). edited by Hollingworth T and Dalton JAW. CRC Press (Taylor & Francis Group, LLC), 2026.

Garg N, **Thorat MA**. Breast/nipple discharge in pregnancy. Differential Diagnosis in Obstetrics & Gynaecology (Third Edition). edited by Hollingworth T and Dalton JAW. CRC Press (Taylor & Francis Group, LLC), 2026.

ABSTRACTS: Please refer to the [Web of Science profile](#).

INVITED TALKS

1. **Breast Cancer Prevention.** Cancer Prevention Europe, webinar, 07 July 2025.
2. **Therapeutic Prevention of Cancer.** Cancer Core Europe Summer School, 07th October 2024, Albufeira, Portugal.
3. **Anastrozole for breast cancer prevention.** The UK-TCPN annual meeting, 24th November 2023.
4. **DCIS - ER, PR and HER2 implications.** iBreastBook Webinar 15th July 2021.
5. **Hormone Replacement Therapy and Cancer.** European Cancer League Webinar; 25th May 2022.
6. **Decoding DCIS (Panelist) - BreastGlobal Webinar** 07 August 2021.
7. **Prognostic Role and multi-clonality of ER expression in DCIS.** BreastGlobal Conference 2021; BreastGlobal- From Crux To Consensus; WEBCONFERENCE; 25-27 June 2021.
8. **H. pylori eradication before prophylactic use of Aspirin.** 11th International ICAPS Conference on Cancer Prevention: Targeting Infection, Inflammation and the Immune System, 9th-10th September 2019, London, UK.
9. **Prognostic and predictive biomarkers in DCIS: HER2, ER expression and multi-clonality of ER expression in the UK/ANZ DCIS trial.** Sola Meeting - Annual meeting of Norwegian Regional Network for Breast Cancer Research, 20-21 September 2018, Stavanger, Norway.
10. Late recurrence in ER positive breast cancer - **PRIMROSE** - PRospective Investigation of Management of long term Recurrence-risk in Oestrogen Receptor positive breast cancer patients. British Breast Group meeting, 29th June 2019, Southampton, UK.
11. **Methodology in Cancer Prevention Research.** Cardiff University – Wales Population Health Conference, 19th June 2019, Cardiff, UK.

12. **Chemoprevention of Cancer - Weighing up the population benefit and potential harm.** Cardiff University – Wales Population Health Conference, 19th June 2019, Cardiff, UK.
13. **Prevention of GI Cancers.** European School of Oncology (ESO) Eurasia Course on Gastrointestinal Malignancies, 18-19 May 2017, Moscow, Russia.
14. **Aspirin in prostate cancer prevention.** Special session of Prostate Cancer Prevention group at the European Association of Urology (EAU) Annual Congress, 24th March 2017, London, UK
15. **Session Chair** at the 10th International Conference on Lung Cancer Prevention, 2nd December 2016, Vienna, Austria.
16. **Prevention of ER+ breast cancers.** International Society of Cancer Prevention (ISCaP) workshop: Medical Prevention of Breast Cancer at 14th St. Gallen International Breast Cancer Conference. Vienna, Austria 18 - 21 March 2015.
17. **DCIS: Role of medical management.** European School of Oncology and Ulm University: Certificate of Competence in Breast Cancer Programme (Online Educational Session).
18. **Panel discussion** on Colorectal Cancer Prevention at the 8th International Conference on Gastrointestinal Cancer Prevention, 24th and 25th June 2014, Barcelona, Spain.
19. **Xpert® HPV: Clinical and analytical performance of the new assay** at Gruppo Italiano Screening del Cervicocarcinoma (GISCI) National Congress, 11th June 2014, Florence, Italy.
20. **Faculty:** ASiT / IJS **How To Get Published Course** at The 2013 Asso. of Surgeons in Training International Surgical Conference. Manchester.